Fate Therapeutics Inc (FATE)
3.87
-0.43
(-10.00%)
USD |
NASDAQ |
Apr 25, 16:00
3.865
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Enterprise Value: 111.55M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 111.55M |
| April 23, 2024 | 135.37M |
| April 22, 2024 | 159.18M |
| April 19, 2024 | 160.18M |
| April 18, 2024 | 184.98M |
| April 17, 2024 | 207.81M |
| April 16, 2024 | 218.73M |
| April 15, 2024 | 244.53M |
| April 12, 2024 | 257.43M |
| April 11, 2024 | 275.29M |
| April 10, 2024 | 307.05M |
| April 09, 2024 | 355.67M |
| April 08, 2024 | 350.71M |
| April 05, 2024 | 371.55M |
| April 04, 2024 | 376.51M |
| April 03, 2024 | 380.48M |
| April 02, 2024 | 359.64M |
| April 01, 2024 | 387.43M |
| March 28, 2024 | 413.23M |
| March 27, 2024 | 413.23M |
| March 26, 2024 | 365.60M |
| March 25, 2024 | 366.59M |
| March 22, 2024 | 340.79M |
| March 21, 2024 | 422.16M |
| March 20, 2024 | 422.16M |
| Date | Value |
|---|---|
| March 19, 2024 | 379.49M |
| March 18, 2024 | 383.46M |
| March 15, 2024 | 428.12M |
| March 14, 2024 | 402.32M |
| March 13, 2024 | 443.00M |
| March 12, 2024 | 444.99M |
| March 11, 2024 | 467.81M |
| March 08, 2024 | 490.64M |
| March 07, 2024 | 513.46M |
| March 06, 2024 | 476.74M |
| March 05, 2024 | 372.54M |
| March 04, 2024 | 387.43M |
| March 01, 2024 | 452.93M |
| February 29, 2024 | 388.42M |
| February 28, 2024 | 393.38M |
| February 27, 2024 | 425.14M |
| February 26, 2024 | 374.53M |
| February 23, 2024 | 375.52M |
| February 22, 2024 | 367.58M |
| February 21, 2024 | 362.62M |
| February 20, 2024 | 385.44M |
| February 16, 2024 | 430.45M |
| February 15, 2024 | 383.11M |
| February 14, 2024 | 324.92M |
| February 13, 2024 | 315.06M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-187.06M
Minimum
Oct 27 2023
10.42B
Maximum
Jan 14 2021
2.496B
Average
1.696B
Median
Enterprise Value Benchmarks
| Amicus Therapeutics Inc | 3.215B |
| Regeneron Pharmaceuticals Inc | 90.64B |
| Sarepta Therapeutics Inc | 11.22B |
| ADMA Biologics Inc | 1.554B |
| Ocular Therapeutix Inc | 569.49M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -44.12M |
| Revenue (Quarterly) | 1.676M |
| Total Expenses (Quarterly) | 49.75M |
| EPS Diluted (Quarterly) | -0.45 |
| Profit Margin (Quarterly) | -2.63K% |
| Earnings Yield | -42.43% |
| Normalized Earnings Yield | -42.43 |